During Thursday’s Midday Trade, next to the material sector stocks, Healthcare sector was best performing sector, higher by 1.9%. The most notable stocks includes Hospira Inc. (NYSE:HSP), and Becton, Dickinson (NYSE: BDX), showing an increase of 35.2% and 4.0%, correspondingly.
Hospira, (HSP), Invacare, (IVC), Ariad Pharmaceuticals, (ARIA), Intercept Pharmaceuticals, (ICPT), Lannett Company, (LCI)’s stocks all were shimmering in response to upbeat trend of Healthcare Sector. Comprehensive details are described as under:
Hospira Inc. (NYSE:HSP), skyrocketed 35.25% to close at $87.64.
Reason: Pfizer Inc. (PFE) and Hospira, Inc. (HSP) declared that they have reached a definitive merger contract under which Pfizer will attain Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 a share in cash for a total enterprise value of about $17 billion. The Boards of Directors of both companies have unanimously approved the merger, which is predictable to be right away accretive upon closing, accretive by $0.10 - $0.12 per share for the first full year following the close of the transaction with additional accretion anticipated thereafter.
Hospira Inc. (NYSE:HSP), is the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill.
Shares of Invacare Corporation, (NYSE:IVC), jumped nearly 18.54% and closed at $17.90, soon after the corporation declared its financial results for the quarter and year ended December 31, 2014. Financial highlights includes Loss per share on a GAAP basis was $0.21 contrast to loss per share of $0.50 in the fourth quarter of the preceding year. Adjusted net loss per share was $0.12 contrast to an adjusted net loss per share of $0.22 in the fourth quarter of the preceding year.
Invacare Corporation, (NYSE:IVC), headquartered in Elyria, Ohio, is the global leader in the manufacture and distribution of innovative home and long-term care medical products that promote recovery and active lifestyles.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), surged 10.24% to close at $6.89, after an integrated global oncology company, declared that it will present at the Leerink Global Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will offer an overview of the Company’s business on Thursday, February 12, at 3:30 p.m. (ET).
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines.
Shares of the Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), enhanced 9.52% & closed at $201.26, as a development stage biopharmaceutical company, declared the pricing of an underwritten public offering of 1,000,000 shares of its ordinary stock at a public offering price of $176.00 per share. In addition, Intercept has granted the underwriters a 30-day option to purchase up to an additional 150,000 shares of ordinary stock.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and other diseases utilizing its expertise in bile acid chemistry.
Lannett Company, Inc. (NYSE:LCI), mounted 7.92% to close at $52.61, following Lannett stated financial results for its fiscal 2015 second quarter ended December 31, 2014. For the fiscal 2015 second quarter, net sales rose 71% to $114.8 million from $67.3 million in last year’s second quarter. Gross profit doubled to $87.2 million, or 76% of net sales, from $41.0 million, or 61% of net sales. Research and development (R&D) expenses raised to $7.8 million from $5.8 million for the fiscal 2014 second quarter. Selling, general and administrative (SG&A) expenses were $12.8 million, contrast with $9.9 million in the same quarter of the preceding year. Operating revenue more than doubled to $66.5 million from $25.4 million for the preceding year second quarter. Net revenue attributable to Lannett Company grew 170% to $44.8 million, or $1.21 per diluted share, from $16.6 million, or $0.46 per diluted share.
Lannett Company, Inc. (NYSE:LCI), founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.
